Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1 * Untreated or previously received one treatment regimen for measurable unresectable stage III or stage IV melanoma (American Joint Committee on Cancer \[AJCC\] 2010) (for BRAF wild-type, and regardless of human leukocyte antigen \[HLA\] type); untreated or previously received up to two treatment regimens for measurable unresectable stage III or stage IV melanoma (AJCC 2010) (for BRAF mutant, and regardless of HLA type; if 2 prior regimens, one should be a BRAF inhibitor); this does not include any therapies given in the adjuvant setting * Prior treatment (chemotherapy \[chemo\], radiation, hormone, and immune therapies) must be completed \> 4 weeks prior to randomization (\> 6 weeks prior to randomization for nitrosoureas, mitomycin C, and checkpoint inhibitors) * Patients who received prior therapy with anthracyclines should have a baseline multigated acquisition scan (MUGA) or echocardiogram (echo) with a normal ejection fraction within 28 days prior to randomization * Patients must have recovered from any acute toxicity associated with prior therapy by the start of study treatment * Women must not be pregnant or breast-feeding due to the unknown effects on the fetus or infant; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual o…